NCT06361212View on ClinicalTrials.gov

Ethoximod Pharmacokinetics In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

September 20, 2022

Study Completion Date

January 12, 2024

Conditions
Psoriasis
Interventions
DRUG

Ethoximod

Ethoximod is a S1P1 modulator.

Trial Locations (1)

Unknown

The first hospital of Jilin University, Changchun

Sponsors

Lead Sponsor

Longevity Inc.
All Listed Sponsors
lead

Longevity Inc.

INDUSTRY

NCT06361212 - Ethoximod Pharmacokinetics In Healthy Subjects | Biotech Hunter | Biotech Hunter